Comment on: Feedback to Tolterodine QTMALHOTRA, B. K; GLUE, P.Clinical pharmacology and therapeutics. 2008, Vol 83, Num 2, pp 233-233, issn 0009-9236, 1 p.Article

Thorough QT study with recommended and supratherapeutic doses of tolterodineMALHOTRA, B. K; GLUE, P; SWEENEY, K et al.Clinical pharmacology and therapeutics. 2007, Vol 81, Num 3, pp 377-385, issn 0009-9236, 9 p.Article

Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlationLIGANG ZHAO; YAN LI; LIANG FANG et al.International journal of pharmaceutics (Print). 2009, Vol 374, Num 1-2, pp 73-81, issn 0378-5173, 9 p.Article

Tolterodine does not affect memory assessed by passive-avoidance response test in miceCAPPON, Gregg D; BUSH, Brian; NEWGREEN, Donald et al.European journal of pharmacology. 2008, Vol 579, Num 1-3, pp 225-228, issn 0014-2999, 4 p.Article

High performance liquid chromatography-electrospray ionization mass spectrometric determination of tolterodine tartrate in human plasmaBEIBEI ZHANG; ZUNJIAN ZHANG; YUAN TIAN et al.Journal of chromatography. B. 2005, Vol 824, Num 1-2, pp 92-98, issn 1570-0232, 7 p.Article

Pressure-flow variables in patients treated with tolterodine for detrusor overactivityWAGG, A; MALONE-LEE, J.BJU international (Papier). 2003, Vol 92, Num 9, pp 969-971, issn 1464-4096, 3 p.Article

Tolterodine for the treatment of urge urinary incontinenceELTERMAN, Dean S; CHUGHTAI, Bilal; KAPLAN, Steven A et al.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 14, pp 1987-1991, issn 1465-6566, 5 p.Article

A validated chiral HPLC method for the enantiomeric separation of tolterodine tartarateRAVINDRA KUMAR, Y; RAMULU, G; VEVAKANAND, V. V et al.Journal of pharmaceutical and biomedical analysis. 2004, Vol 35, Num 5, pp 1279-1285, issn 0731-7085, 7 p.Article

The efficacy of tolterodine for prevention of catheter- related bladder discomfort : A prospective, randomized, placebo-controlled, double-blind studyAGARWAL, Anil; RAZA, Mehdi; SINGHAL, Vinay et al.Anesthesia and analgesia. 2005, Vol 101, Num 4, pp 1065-1067, issn 0003-2999, 3 p.Article

Selective prescribing of spasmolyticsMOVIG, K. L. L; EGBERTS, A. C. G; LENDERINK, A. W et al.The Annals of pharmacotherapy. 2000, Vol 34, Num 6, pp 716-720, issn 1060-0280Article

Miscibility study of carrageenan blends and evaluation of their effectiveness as sustained release carriersNANAKI, Stavroula; KARAVAS, Evangelos; KALANTZI, Lida et al.Carbohydrate polymers. 2010, Vol 79, Num 4, pp 1157-1167, issn 0144-8617, 11 p.Article

Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladderMICHEL, Martin C; DE LA ROSETTE, Jean J. M. C. H; PIRO, Maria et al.European urology. 2005, Vol 48, Num 1, pp 110-115, issn 0302-2838, 6 p.Article

Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladderRAES, A; HOEBEKE, P; SEGAERT, I et al.European urology. 2004, Vol 45, Num 2, pp 240-244, issn 0302-2838, 5 p.Article

Development and Validation of a New Analytical Method for the Determination of Related Components in Tolterodine Tartarate Using LCMADHAVI, A; REDDY, G. S; SURYANARAYANA, M. V et al.Chromatographia (Wiesbaden). 2008, Vol 68, Num 5-6, pp 399-407, issn 0009-5893, 9 p.Article

Utility of Nanosized Microemulsion for Transdermal Delivery of Tolterodine Tartrate: Ex-Vivo Permeation and In-Vivo Pharmacokinetic StudiesELSHAFEEY, Ahmed H; KAMEL, Amany O; FATHALLAH, Mohsen M et al.Pharmaceutical research. 2009, Vol 26, Num 11, pp 2446-2453, issn 0724-8741, 8 p.Article

Treatment outcomes in the STAR study : A subanalysis of solifenacin 5 mg and tolterodine ER 4 mgCHAPPLE, Christopher R; FIANU-JONSSON, Aino; INDIG, Mark et al.European urology. 2007, Vol 52, Num 4, pp 1195-1203, issn 0302-2838, 9 p.Article

Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥50 yearsDIEFENBACH, Konstanze; AROLD, Gerhard; WOLLNY, Agnes et al.BJU international (Papier). 2005, Vol 95, Num 3, pp 346-349, issn 1464-4096, 4 p.Article

Efficacy of tolterodine as a first-line treatment for non-neurogenic voiding dysfunction in childrenAYAN, Semih; KAYA, Kemal; TOPSAKAL, Kahraman et al.BJU international (Papier). 2005, Vol 96, Num 3, pp 411-414, issn 1464-4096, 4 p.Article

Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteersHUA, Teng C; PAN, Alan; CHAN, Clark et al.British journal of clinical pharmacology. 2004, Vol 57, Num 5, pp 652-656, issn 0306-5251, 5 p.Article

A process for the rapid removal of dialkylamino-substituents from aromatic rings. Application to the expedient synthesis of (R)-tolterodinePARAS, Nick A; SIMMONS, Bryon; MACMILLAN, David W. C et al.Tetrahedron (Oxford. Print). 2009, Vol 65, Num 16, issn 0040-4020, 3033, 3232-3238 [8 p.]Article

Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in miceOKI, Tomomi; MARUYAMA, Shuji; TAKAGI, Yukiko et al.European journal of pharmacology. 2006, Vol 529, Num 1-3, pp 157-163, issn 0014-2999, 7 p.Article

Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles : A subanalysis of data from the OPERA trial. DiscussionCHU, Franklin M; DMOCHOWSKI, Roger R; LAMA, Daniel J et al.American journal of obstetrics and gynecology. 2005, Vol 192, Num 6, pp 1849-1855, issn 0002-9378, 7 p.Conference Paper

Does gender or age affect the efficacy and safety of tolterodine?MICHEL, Martin C; SCHNEIDER, Tim; KREGE, Susanne et al.The Journal of urology. 2002, Vol 168, Num 3, pp 1027-1031, issn 0022-5347Article

Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous systemTODOROVA, Anelia; VONDERHEID-GUTH, Betting; DIMPFEL, Wilfried et al.Journal of clinical pharmacology. 2001, Vol 41, Num 6, pp 636-644, issn 0091-2700Article

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodineBRYNNE, N; DALEN, P; ALVAN, G et al.Clinical pharmacology and therapeutics. 1998, Vol 63, Num 5, pp 529-539, issn 0009-9236Article